Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
65.68
Dollar change
-0.49
Percentage change
-0.74
%
IndexNDX, S&P 500 P/E183.11 EPS (ttm)0.36 Insider Own0.09% Shs Outstand1.25B Perf Week-3.01%
Market Cap81.83B Forward P/E9.20 EPS next Y7.14 Insider Trans-2.22% Shs Float1.24B Perf Month0.63%
Income484.00M PEG32.93 EPS next Q1.59 Inst Own85.61% Short Float1.74% Perf Quarter-9.97%
Sales27.42B P/S2.98 EPS this Y-43.90% Inst Trans0.85% Short Ratio3.15 Perf Half Y-13.24%
Book/sh14.08 P/B4.67 EPS next Y89.40% ROA0.82% Short Interest21.70M Perf Year-16.91%
Cash/sh4.86 P/C13.51 EPS next 5Y5.56% ROE2.51% 52W Range64.33 - 87.86 Perf YTD-18.92%
Dividend Est.3.13 (4.77%) P/FCF10.36 EPS past 5Y1.55% ROI1.24% 52W High-25.25% Beta0.22
Dividend TTM3.02 (4.60%) Quick Ratio0.94 Sales past 5Y4.16% Gross Margin77.68% 52W Low2.10% ATR (14)1.14
Dividend Ex-DateMar 14, 2024 Current Ratio1.08 EPS Y/Y TTM-91.37% Oper. Margin34.04% RSI (14)41.20 Volatility1.65% 1.71%
Employees18000 Debt/Eq1.44 Sales Y/Y TTM2.13% Profit Margin1.77% Recom2.18 Target Price82.25
Option/ShortYes / Yes LT Debt/Eq1.23 EPS Q/Q-517.48% Payout66.62% Rel Volume0.87 Prev Close66.17
Sales Surprise5.17% EPS Surprise11.60% Sales Q/Q5.66% EarningsApr 25 AMC Avg Volume6.89M Price65.68
SMA20-0.90% SMA50-4.30% SMA200-12.75% Trades Volume5,966,633 Change-0.74%
Date Action Analyst Rating Change Price Target Change
May-01-24Reiterated Maxim Group Buy $90 → $85
Apr-24-24Upgrade HSBC Securities Reduce → Hold $69
Feb-22-24Downgrade Truist Buy → Hold $91 → $82
Nov-09-23Initiated Deutsche Bank Hold $75
Sep-08-23Upgrade BofA Securities Neutral → Buy $88 → $95
Sep-06-23Initiated HSBC Securities Reduce $71
Jul-24-23Reiterated Barclays Equal Weight $81 → $80
May-16-23Upgrade BMO Capital Markets Market Perform → Outperform $90 → $100
Apr-28-23Resumed Piper Sandler Overweight $105
Jan-03-23Downgrade RBC Capital Mkts Outperform → Sector Perform $87
May-25-24 11:10PM
May-22-24 05:17PM
10:48AM
08:30AM
May-21-24 10:15AM
09:00AM Loading…
09:00AM
May-20-24 11:36AM
10:43AM
May-18-24 08:30AM
08:06AM
May-17-24 08:06AM
May-16-24 02:27PM
May-14-24 10:09AM
08:45AM
May-13-24 12:41PM
09:00AM Loading…
May-10-24 09:00AM
May-09-24 04:05PM
04:05PM
09:45AM
06:49AM
01:07AM
May-07-24 09:45AM
08:30AM
May-06-24 12:39PM
May-04-24 07:38AM
May-03-24 08:11PM
02:00PM
May-02-24 11:29AM
May-01-24 02:38PM
10:53AM
10:19AM Loading…
10:19AM
08:25AM
Apr-30-24 04:05PM
12:01PM
Apr-29-24 09:00AM
08:18AM
06:01AM
Apr-28-24 05:50PM
Apr-26-24 04:31PM
04:10PM
11:44AM
10:45AM
10:24AM
10:09AM
10:08AM
09:59AM
09:14AM
08:11AM
08:00AM
03:35AM
Apr-25-24 09:45PM
06:00PM
05:49PM
05:41PM
05:15PM
04:59PM
04:50PM
04:40PM
04:14PM
04:11PM
04:07PM
04:02PM
04:02PM
Apr-22-24 01:57PM
09:16AM
Apr-19-24 05:50PM
Apr-18-24 06:33PM
06:00PM
01:45PM
10:01AM
Apr-17-24 02:03AM
Apr-16-24 09:00AM
Apr-15-24 08:00AM
01:06AM
12:22AM
Apr-12-24 06:00PM
Apr-11-24 09:15AM
Apr-10-24 06:09PM
Apr-09-24 06:15PM
02:40PM
07:37AM
Apr-08-24 04:05PM
Apr-06-24 06:49AM
Apr-05-24 08:30AM
Apr-03-24 09:00AM
Apr-02-24 06:00PM
09:15AM
Mar-28-24 08:30AM
07:00AM
06:45AM
06:45AM
Mar-26-24 09:15AM
05:15AM
Mar-25-24 06:00PM
Mar-22-24 09:18AM
Mar-20-24 09:00AM
Mar-19-24 06:00PM
09:05AM
Mar-18-24 07:29PM
08:00AM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Parsey MerdadChief Medical OfficerApr 01 '24Sale72.962,000145,92096,304Apr 02 06:38 PM
Parsey MerdadChief Medical OfficerFeb 29 '24Sale72.748,230598,62492,706Feb 29 06:35 PM
Parsey MerdadChief Medical OfficerFeb 28 '24Sale73.182,000146,360100,936Feb 29 06:35 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
GILEAD SCIENCES, INC.10% OwnerJan 29 '24Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Dickinson Andrew DChief Financial OfficerJan 16 '24Sale85.785,000428,900101,534Jan 17 06:01 PM
Mercier JohannaChief Commercial OfficerJan 09 '24Sale85.238,242702,46682,729Jan 10 03:58 PM
Dickinson Andrew DChief Financial OfficerOct 17 '23Sale80.005,000400,017104,003Oct 18 04:31 PM
Parsey MerdadChief Medical OfficerSep 12 '23Sale76.991,501115,56270,130Sep 13 06:50 PM
Dickinson Andrew DChief Financial OfficerJul 20 '23Sale80.005,000400,000107,587Jul 21 05:30 PM
GILEAD SCIENCES, INC.10% OwnerJun 28 '23Buy19.261,010,00019,452,60014,823,029Jun 30 03:12 PM
GILEAD SCIENCES, INC.10% OwnerJun 27 '23Buy3.752,930,87010,990,76216,635,286Jun 28 05:17 PM
Parsey MerdadChief Medical OfficerJun 13 '23Sale76.901,485114,19729,402Jun 14 05:48 PM